Value through Innovation30 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

17.02.2014

Boehringer Ingelheim Receives East Bay Innovation Award

07.01.2014

Crystal Bioscience and Boehringer Ingelheim Announce Multiple Target Antibody Discovery Collaboration

20.12.2013

Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product

- For Non-US and Non-UK Media  
18.12.2013

Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders

17.12.2013

New data on safety and efficacy of Pradaxa® in treatment of acute deep vein thrombosis and pulmonary embolism

- For media outside of the US, the UK & Canada only
16.12.2013

Hepatitis C: Phase III data show Boehringer Ingelheim’s faldaprevir* is effective even in patients with common drug-resistant viral variant

- For media outside of the US, the UK & Canada only
10.12.2013

New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism*

- For media outside of the US, the UK & Canada only
03.12.2013

New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes

- For Non-US and Non-UK Media
02.12.2013

Largest global survey investigating early Type 2 Diabetes conversations launched by Boehringer Ingelheim and Eli Lilly and Company in partnership with the International Diabetes Federation

- For Non-US and Non-UK Media
26.11.2013

Hepatitis C: Boehringer Ingelheim’s faldaprevir granted accelerated assessment from European Medicines Agency

- For media outside of the U.S.A., UK and Canada only
25.11.2013

Pradaxa® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY® – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do not change the position of Pradaxa®

- For media outside of the US, the UK & Canada only
19.11.2013

New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years

- For media outside of the US, the UK & Canada only
19.11.2013

Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations

- For media outside of the US, the UK & Canada only
18.11.2013

First human data show promise of Boehringer Ingelheim's specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation

- For media outside of the US, the UK & Canada only
15.11.2013

Boehringer Ingelheim goes "Blue" in supporting World Diabetes Day activities

13.11.2013

Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and over

- For Media outside the U.S., Canada and UK
12.11.2013

Boehringer Ingelheim supports victims of typhoon Haiyan in the Philippines


12.11.2013

New efficacy and safety data for Pradaxa® (dabigatran etexilate) to be announced at American Heart Association's Scientific Sessions 2013

- For media outside of the US, the UK & Canada only